We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.16 | 0.33% | 49.15 | 49.10 | 48.55 | 49.10 | 16,057,438 | 01:00:00 |
From Apr 2022 to Apr 2024
By Sabela Ojea
Shares of Autolus Therapeutics Ltd. on Tuesday rose 14% after the U.K. leukemia drug maker announced the signing of collaboration agreement for the treatment of cancer with pharmaceutical company Bristol Myers Squibb Co.
In premarket trading, the stock was up $2.49 after it closed at $2.18 Monday. The shares have fallen more than 50% so far this year.
The biopharmaceutical will receive an upfront payment from Bristol Myers, with the potential to exercise option fees, development milestone payments and royalties, the company said without disclosing details.
Through the agreement, Autolus said it will grant Bristol Myers access to its Rituximab Safety Switch RQR8 to develop a selection of cell therapy programs for the treatment of cancer.
Bristol Myers will have the option to incorporate the RQR8 safety switch in additional cell therapy programs beyond the initial set of selected programs, the company said.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
October 04, 2022 08:02 ET (12:02 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
